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Clinical Efficacy of Sildenafil
in Primary Pulmonary Hypertension
In the report entitled “Clinical Efficacy of Sildenafil in Primary
Pulmonary Hypertension: A Randomized, Placebo-Controlled,
Double-Blind, Crossover Study” (1) the investigators cite an
impressive short-term improvement in exercise capacity in patients
with pulmonary arterial hypertension (PPH) and who are taking
daily oral sildenafil. The researchers compare their patients’ im-
provement in exercise capacity with sildenafil to that of prior
studies of oral bosentan, oral beraprost, and aerosolized iloprost.
Although their earlier uncontrolled study, which used 6-min walk
testing, suggested an improvement in walk distance of 40% over
baseline (2), their more recent placebo-controlled study, which
used submaximal exercise duration on a treadmill, showed a 44%
increase in exercise time. This improvement was favorably com-
pared to bosentan, beraprost, and iloprost, whose improvement in
6-min walk distance ranged from only 12% to 21%.
We applaud the investigators’ choice of measuring exercise
endurance over a 6-min walk distance as a measure of exercise
capacity end point for patients with PPH. However, we believe
that these comparisons of sildenafil with other pulmonary vascular
drugs should be interpreted cautiously, because: 1) the patient
population in each study was not the same and 2) the 6-min walk
distance and treadmill exercise endurance times are not comparable
in terms of percent change. Oga et al. (3) have shown that
submaximal exercise endurance time is a much more sensitive
indicator of change in exercise capacity than the 6-min walk
distance or peak VO2. In that study, a 19% increase in exercise
duration paralleled a much smaller, although significant, 1%
increase in 6-min walk distance after treatment of chronic obstruc-
tive pulmonary disease patients with an inhaled anticholinergic
agent.
In measuring exercise capacity, the percent improvement in
endurance time likely depends on the level of exercise, particularly
with respect to the chosen exercise protocol (constant vs. incre-
mental work rate protocol). Thus, in this latest sildenafil study, the
44% increase in exercise duration probably overestimates the
improvement that would have been seen had the 6-min walk
distance been used to measure exercise capacity.
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REPLY
We appreciate the interest of Drs. Oudiz and Wasserman in our
study (1). Our primary objective was to compare sildenafil with
placebo in improving the exercise capacity in patients with primary
pulmonary hypertension. From this study, we did not mean to
conclude that sildenafil is superior to other pulmonary vasodilators
like bosentan; beraprost, iloprost, and others.
Improvement in exercise capacity can be measured by different
means including 6-min walk distance, submaximal exercise time,
and maximum oxygen uptake during exercise (VO2 max). These
tests measure different physiological parameters. In a group of
patients treated by the same intervention, different tests may
demonstrate different degrees of improvement depending upon the
method chosen. Even different exercise protocols may give differ-
ent results. As was pointed out, nearly 40% improvement in
exercise time using the Naughton protocol need not result in
similar degree of improvement in 6-min walk distance. Interest-
ingly, however, apart from our initial study, other investigators also
have reported a similar degree of improvement (ranging from 30%
to 50%) in 6-min walk distance with sildenafil in pulmonary
hypertension patients (2–5). It is possible that the exercise on
treadmill test using the Naughton protocol may give similar results
to the 6-min walk test, unlike the kind of exercise protocol used by
Oga et al. (6) in their studies.
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True Uncomplicated Obesity
Is Not Related to Increased Left
Ventricular Mass and Systolic Dysfunction
I found the recent study by Peterson et al. (1) to be quite
interesting. They found that obesity in young and otherwise
healthy women is associated with increased left ventricle (LV)
mass, LV concentric remodeling, and decreased systolic and
diastolic function. I applaud that LV function and diastolic and
systolic functions were obtained by use of second harmonic
imaging and tissue Doppler imaging, a highly sensitive and specific
echocardiographic technique. This procedure allowed the investi-
gators a very accurate evaluation of LV parameters. Nevertheless,
I have some comments on the study design and the results.
The first and main criticism is related to the inclusion criteria
that they applied to define “healthy” obese women. The researchers
put fasting glucose 126 mg/dl or a glucose level 200 mg/dl 2 h
after an oral glucose tolerance test (OGTT) and total cholesterol
level 260 mg/dl and/or triglyceride level 400 mg/dl as cut-off
points to exclude the presence of diabetes mellitus and dyslipide-
mia, respectively. These parameters do not fill the Adult Treat-
ment Panel III guidelines for cardiovascular risk factors (2).
According to the criteria applied in the Peterson et al. (1) study, it
is also not possible to exclude the presence of impaired fasting
glucose and glucose intolerance assessed by fasting glucose between
110 and 125 mg/dl and glucose 140 mg/dl 2 h after an OGTT,
respectively (3). The cut-off point of 400 mg/dl for triglycerides is
not acceptable to define a normal plasma lipid profile. In addition,
the investigators do not report data on high-density lipoprotein
cholesterol (HDL-C) and low- density lipoprotein cholesterol,
widely recognized as cardiac risk factors. Hence, there is no
evidence that these obese women are healthy subjects.
The presence of underevaluated co-morbidities could explain
the finding of increased LV mass and diastolic and systolic
dysfunction in these obese women. In fact, the impact of impaired
fasting glucose, glucose intolerance, low HDL-C, and hypertri-
glyceridemia on LV parameters is well known.
We agree with Peterson et al. (1) that the effects of obesity on
cardiac structure and function in young and otherwise healthy
subjects are still debated. We have performed an investigation on
the influence of excess fat only on cardiac morphology and
function (4). That study showed that obesity per se, although a
disease of long duration, in absence of glucose intolerance, im-
paired fasting glucose, diabetes, hypertension, and dyslipidemia, is
associated only with an impairment of diastolic function and
hyperkinetic systole and not with LV hypertrophy. Obese subjects
without any co-morbidities, called “uncomplicated” obese subjects,
present left atrium and aortic root enlargement as consequences of
impaired diastole and hyperdynamic systole. Hyperkinetic systole,
estimated by both endocardial and midwall parameters, seems to
be due to the increased cardiac work necessary to supply a high
oxygen consumption for the large body surface of obese subjects.
We have not found increased LV mass or true LV hypertrophy in
uncomplicated obese subjects, and insulin resistance seems to be a
determinant of LV mass stronger than body mass index (5).
Nevertheless, this issue is still controversial.
In addition, obese subjects showed an increase of preload,
probably also due to hyperinsulinemia and its sodium retentive
action, leading to the development of LV eccentricity more than
LV concentric remodeling.
The very restricted inclusion criteria that we applied in our
studies in defining “uncomplicated obesity” allowed us to estimate
the influence of obesity per se on LV parameters.
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